
Aurélie Chauffour

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6628691/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 2020, 14, e0007857.	3.0	10
2	Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros. Frontiers in Microbiology, 2020, 11, 711.	3.5	15
3	Fully weekly antituberculosis regimen: a proof-of-concept study. European Respiratory Journal, 2020, 56, 1902502.	6.7	3
4	Title is missing!. , 2020, 14, e0007857.		0
5	Title is missing!. , 2020, 14, e0007857.		0
6	Title is missing!. , 2020, 14, e0007857.		0
7	Title is missing!. , 2020, 14, e0007857.		0
8	Title is missing!. , 2020, 14, e0007857.		0
9	Title is missing!. , 2020, 14, e0007857.		0
10	Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15. Clinical Microbiology and Infection, 2018, 24, 1305-1310.	6.0	113
11	Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer. Nature Communications, 2018, 9, 5370.	12.8	64
12	Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?. Journal of Antimicrobial Chemotherapy, 2017, 72, 2326-2333.	3.0	24
13	In vivo Mycobacterium tuberculosisfluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. Journal of Antimicrobial Chemotherapy, 2016, 71, 3465-3472.	3.0	9
14	Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. PLoS Neglected Tropical Diseases, 2016, 10, e0005066.	3.0	23
15	New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories. PLoS Neglected Tropical Diseases, 2015, 9, e0004141.	3.0	15
16	Aedesin: Structure and Antimicrobial Activity against Multidrug Resistant Bacterial Strains. PLoS ONE, 2014, 9, e105441.	2.5	11
17	Resistance of M. leprae to Quinolones: A Question of Relativity?. PLoS Neglected Tropical Diseases, 2013, 7, e2559.	3.0	11
18	Impact of Fluoroquinolone Resistance on Bactericidal and Sterilizing Activity of a Moxifloxacin-Containing Regimen in Murine Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4496-4500.	3.2	20

Aurélie Chauffour

#	Article	IF	CITATIONS
19	Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model. Antimicrobial Agents and Chemotherapy, 2012, 56, 687-696.	3.2	23
20	Should Moxifloxacin Be Used for the Treatment of Extensively Drug-Resistant Tuberculosis? An Answer from a Murine Model. Antimicrobial Agents and Chemotherapy, 2010, 54, 4765-4771.	3.2	70
21	Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against <i>Mycobacterium ulcerans</i> in Mice. Antimicrobial Agents and Chemotherapy, 2009, 53, 2955-2959.	3.2	6
22	A Once-Weekly R207910-containing Regimen Exceeds Activity of the Standard Daily Regimen in Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 75-79.	5.6	63
23	Bactericidal and Sterilizing Activities of Several Orally Administered Combined Regimens against <i>Mycobacterium ulcerans</i> in Mice. Antimicrobial Agents and Chemotherapy, 2008, 52, 1912-1916.	3.2	31
24	Curing Mycobacterium ulcerans Infection in Mice with a Combination of Rifampin-Streptomycin or Rifampin-Amikacin. Antimicrobial Agents and Chemotherapy, 2007, 51, 645-650.	3.2	23
25	Orally Administered Combined Regimens for Treatment of <i>Mycobacterium ulcerans</i> Infection in Mice. Antimicrobial Agents and Chemotherapy, 2007, 51, 3737-3739.	3.2	57
26	In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial Agents and Chemotherapy, 2006, 50, 1921-1926.	3.2	100
27	Dihydropteroate Synthase Mutations in the folP1 Gene Predict Dapsone Resistance in Relapsed Cases of Leprosy. Clinical Infectious Diseases, 2006, 42, 238-241.	5.8	47
28	Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. Antimicrobial Agents and Chemotherapy, 2006, 50, 3543-3547.	3.2	127
29	Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria. Antimicrobial Agents and Chemotherapy, 2006, 50, 2853-2856.	3.2	125
30	Bactericidal Activities of R207910 and Other Newer Antimicrobial Agents against <i>Mycobacterium leprae</i> in Mice. Antimicrobial Agents and Chemotherapy, 2006, 50, 1558-1560.	3.2	45